Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Generation of proliferating human hepatocytes using Upcyte® technology: characterisation and applications in induction and cytotoxicity assays.

Burkard A, Dähn C, Heinz S, Zutavern A, Sonntag-Buck V, Maltman D, Przyborski S, Hewitt NJ, Braspenning J.

Xenobiotica. 2012 Oct;42(10):939-56. doi: 10.3109/00498254.2012.675093. Epub 2012 Apr 24.

PMID:
22524704
2.

Applicability of second-generation upcyte® human hepatocytes for use in CYP inhibition and induction studies.

Ramachandran SD, Vivarès A, Klieber S, Hewitt NJ, Muenst B, Heinz S, Walles H, Braspenning J.

Pharmacol Res Perspect. 2015 Oct;3(5):e00161. doi: 10.1002/prp2.161. Epub 2015 Aug 10.

3.

Follow-up to the pre-validation of a harmonised protocol for assessment of CYP induction responses in freshly isolated and cryopreserved human hepatocytes with respect to culture format, treatment, positive reference inducers and incubation conditions.

Abadie-Viollon C, Martin H, Blanchard N, Pekthong D, Bachellier P, Mantion G, Heyd B, Schuler F, Coassolo P, Alexandre E, Richert L.

Toxicol In Vitro. 2010 Feb;24(1):346-56. doi: 10.1016/j.tiv.2009.05.021. Epub 2009 Jun 2.

PMID:
19497360
4.

Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.

Tolosa L, Gómez-Lechón MJ, López S, Guzmán C, Castell JV, Donato MT, Jover R.

Toxicol Sci. 2016 Jul;152(1):214-29. doi: 10.1093/toxsci/kfw078. Epub 2016 May 4.

PMID:
27208088
5.

Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies.

Jossé R, Aninat C, Glaise D, Dumont J, Fessard V, Morel F, Poul JM, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2008 Jun;36(6):1111-8. doi: 10.1124/dmd.107.019901. Epub 2008 Mar 17.

6.

Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up.

Meunier V, Bourrié M, Julian B, Marti E, Guillou F, Berger Y, Fabre G.

Xenobiotica. 2000 Jun;30(6):589-607.

PMID:
10923861
8.

Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells.

Westerink WM, Schoonen WG.

Toxicol In Vitro. 2007 Dec;21(8):1581-91. Epub 2007 Jun 8.

PMID:
17637504
9.

Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures.

Herzog N, Hansen M, Miethbauer S, Schmidtke KU, Anderer U, Lupp A, Sperling S, Seehofer D, Damm G, Scheibner K, Küpper JH.

Cell Biol Int. 2016 Mar;40(3):341-53. doi: 10.1002/cbin.10574. Epub 2016 Jan 18.

PMID:
26715207
10.

Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells.

Aninat C, Piton A, Glaise D, Le Charpentier T, Langouët S, Morel F, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2006 Jan;34(1):75-83. Epub 2005 Oct 4.

11.

Comparison of basal gene expression and induction of CYP3As in HepG2 and human fetal liver cells.

Maruyama M, Matsunaga T, Harada E, Ohmori S.

Biol Pharm Bull. 2007 Nov;30(11):2091-7.

12.

Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.

Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA.

Cell Biol Toxicol. 2012 Apr;28(2):69-87. doi: 10.1007/s10565-011-9208-4. Epub 2012 Jan 19.

13.

The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.

Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C.

Chem Biol Interact. 2007 May 20;168(1):66-73. Epub 2006 Dec 16. Review.

PMID:
17241619
14.

Chemically induced hepatotoxicity in human stem cell-induced hepatocytes compared with primary hepatocytes and HepG2.

Kang SJ, Lee HM, Park YI, Yi H, Lee H, So B, Song JY, Kang HG.

Cell Biol Toxicol. 2016 Oct;32(5):403-17. doi: 10.1007/s10565-016-9342-0. Epub 2016 Jun 11.

PMID:
27287938
15.

Stable expression, activity, and inducibility of cytochromes P450 in differentiated HepaRG cells.

Anthérieu S, Chesné C, Li R, Camus S, Lahoz A, Picazo L, Turpeinen M, Tolonen A, Uusitalo J, Guguen-Guillouzo C, Guillouzo A.

Drug Metab Dispos. 2010 Mar;38(3):516-25. doi: 10.1124/dmd.109.030197. Epub 2009 Dec 17.

16.

Optimization of upcyte® human hepatocytes for the in vitro micronucleus assay.

Nörenberg A, Heinz S, Scheller K, Hewitt NJ, Braspenning J, Ott M.

Mutat Res. 2013 Dec 12;758(1-2):69-79. doi: 10.1016/j.mrgentox.2013.09.008. Epub 2013 Oct 16.

PMID:
24140631
17.

Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction.

Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM.

Drug Metab Dispos. 2006 Oct;34(10):1742-8. Epub 2006 Jul 12.

18.

In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes.

Jackson JP, Kabirov KK, Kapetanovic IM, Lyubimov A.

Chem Biol Interact. 2009 May 15;179(2-3):263-72. doi: 10.1016/j.cbi.2008.12.005. Epub 2008 Dec 16.

PMID:
19135037
19.

HepG2 cells as an in vitro model for evaluation of cytochrome P450 induction by xenobiotics.

Choi JM, Oh SJ, Lee SY, Im JH, Oh JM, Ryu CS, Kwak HC, Lee JY, Kang KW, Kim SK.

Arch Pharm Res. 2015;38(5):691-704. doi: 10.1007/s12272-014-0502-6. Epub 2014 Oct 22.

PMID:
25336106
20.

Assessment of cytochrome P450 (1A2, 2B6, 2C9 and 3A4) induction in cryopreserved human hepatocytes cultured in 48-well plates using the cocktail strategy.

Gerin B, Dell'Aiera S, Richert L, Smith S, Chanteux H.

Xenobiotica. 2013 Apr;43(4):320-35. doi: 10.3109/00498254.2012.719088. Epub 2012 Nov 15.

PMID:
23153057

Supplemental Content

Support Center